Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 39

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

579

HTML

4145

Figures (1-2)

308

Tables (1-2)

211

Sum=5243

Publishing Process of This Article

Item

Count

Browse

992

Download

1055

Sum=2047

Oct 21, 2013 (publication date) through Dec 29, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastroenterol. Oct 21, 2013; 19(39): 6665-6678
Published online Oct 21, 2013. doi: 10.3748/wjg.v19.i39.6665

Full Size Figure Download Figure

Figure 1 Flow diagram of the randomized controlled trials reviewed. RCT: Randomized controlled trial; ETV: Entecavir; LAM: Lamivudine.

Citation: Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis. World J Gastroenterol 2013; 19(39): 6665-6678
URL: https://www.wjgnet.com/1007-9327/full/v19/i39/6665.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i39.6665